TABLE 2.
MRSA 11/11-REF2145 and CB5053-CB5054 counts in target tissues with DAP and/or OX treatment in the IE model
| Group (no. of animals)a |
S. aureus density (log10 CFU/g tissue) inb: |
||
|---|---|---|---|
| Vegetation | Kidney | Spleen | |
| Control without treatment | |||
| MRSA 11/11 (8) | 7.74 ± 0.79 | 5.51 ± 0.63 | 5.28 ± 0.56 |
| MRSA REF2145 (8) | 8.84 ± 0.56 | 6.29 ± 0.67 | 6.15 ± 0.65 |
| CB5053 (6) | 7.74 ± 0.80 | 5.98 ± 0.98 | 5.84 ± 0.53 |
| CB5054 (6) | 8.76 ± 0.18 | 6.63 ± 0.75 | 5.95 ± 0.65 |
| Treatment | |||
| MRSA 11/11 (12 mg/kg DAP i.v. once daily) (7) | 1.58 ± 0.59 | 0.53 ± 0.28 | 0.60 ± 0.16 |
| MRSA REF2145 (12 mg/kg DAP i.v. once daily) (7) | 7.93 ± 1.12* | 6.74 ± 0.71* | 5.52 ± 1.23* |
| MRSA 11/11 (200 mg/kg OX i.m. t.i.d.) (8) | 5.96 ± 2.23 | 3.99 ± 1.43 | 4.07 ± 1.17 |
| MRSA REF2145 (200 mg/kg OX i.m. t.i.d.) (8) | 7.21 ± 1.39 | 5.09 ± 1.99 | 4.79 ± 1.51 |
| MRSA REF2145 (DAP-OX) (8) | 4.20 ± 1.61** | 2.90 ± 1.50** | 3.12 ± 0.81** |
| CB5053 (12 mg/kg DAP i.v. once daily) (6) | 1.71 ± 0.96 | 0.95 ± 0.60 | 1.07 ± 0.92 |
| CB5054 (12 mg/kg DAP i.v. once daily) (6) | 8.34 ± 0.83* | 6.32 ± 1.31* | 5.78 ± 1.29* |
| CB5053 (200 mg/kg OX i.m. t.i.d.) (7) | 6.18 ± 1.74 | 4.01 ± 1.82 | 3.88 ± 1.19 |
| CB5054 (200 mg/kg OX i.m. t.i.d.) (6) | 8.96 ± 0.44 | 6.35 ± 1.02 | 5.68 ± 0.80 |
| CB5054 (DAP-OX) (10) | 5.70 ± 1.98** | 3.88 ± 1.25** | 3.99 ± 0.95** |
a
12 mg/kg DAP intravenously (i.v.) once daily is equivalent to a dose of 6 mg/kg once daily in humans (7).
b
*, P value of <0.001 relative to the value for DAPs MRSA 11/11 or CB5053 with DAP treatment; **, P value of <0.05 relative to the value for REF2145 or CB5054 with OX-only or DAP-only treatment.